Fig. 7
From: Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma
The metabolic and therapeutic correlations of CR risk score. A-G The associations of CR risk score with the enrichments of multiple metabolic process based on GSEA analysis. H The difference in CR risk score between Sorafenib-response and -nonresponse patients based on GSE109211 cohort. I The difference in TMB between high- and low-CR risk groups. J The results of TIDE analyses. K The expressive differences of six ICs between high- and low-CR risk groups. L The difference in CR risk score between ICB-response and -nonresponse patients based on IMvigor 210 cohort. ICs, immune checkpoints; *P < 0.05, **P < 0.01, ***P < 0.001